Macrocure

Leap Therapeutics, Macrocure to merge

Wednesday, September 7, 2016

Leap Therapeutics, a clinical stage immuno-oncology company, and Macrocure have announced the signing of a definitive merger agreement. Under the terms of the agreement, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company. In connection with the transaction, Leap will apply to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger.

[Read More]